In multiple myeloma, myeloma cells secrete DKK1 and SFRPs to block which signaling pathway?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Study for the Mandible, TMJ, Bone Modeling Test. Enhance your knowledge with diverse questions, explanations, and hints. Prepare confidently for your successful exam attempt!

Multiple Choice

In multiple myeloma, myeloma cells secrete DKK1 and SFRPs to block which signaling pathway?

Explanation:
The main idea is that DKK1 and SFRPs act as antagonists of the Wnt signaling pathway. DKK1 binds to the LRP5/6 co-receptors, blocking the Wnt receptor complex from forming and preventing stabilization of β-catenin. SFRPs bind Wnt ligands themselves, sequestering them away from Frizzled receptors. With canonical Wnt signaling inhibited, osteoblast differentiation and bone formation are reduced, which contributes to the osteolytic lesions seen in multiple myeloma. The other pathways listed (BMP, RANKL, Notch) aren’t the primary targets of these inhibitors in this context.

The main idea is that DKK1 and SFRPs act as antagonists of the Wnt signaling pathway. DKK1 binds to the LRP5/6 co-receptors, blocking the Wnt receptor complex from forming and preventing stabilization of β-catenin. SFRPs bind Wnt ligands themselves, sequestering them away from Frizzled receptors. With canonical Wnt signaling inhibited, osteoblast differentiation and bone formation are reduced, which contributes to the osteolytic lesions seen in multiple myeloma. The other pathways listed (BMP, RANKL, Notch) aren’t the primary targets of these inhibitors in this context.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy